DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quibron-T (Theophylline, Anhydrous) - Summary

 
 



QUIBRON-T SUMMARY

QUIBRON®-T
(Theophylline Tablets USP)
ACCUDOSE® Tablets
IMMEDIATE-RELEASE BRONCHODILATOR

Theophylline is structurally classified as a methylxanthine.

Quibron-T is available as tablets intended for oral administration, containing 300 mg of anhydrous theophylline per tablet. Quibron-T is an oral bronchodilator in an immediate-release formulation in the ACCUDOSE Tablet design. With functional trisects and bisects, Quibron-T Tablets can be accurately divided into 100-, 150-, and 200-mg segments to provide a variety of dosing increments, as required.

Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.


See all Quibron-T indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Quibron-T (Theophylline)

Inhaled Steroids May Suppress Growth in Children With Asthma
Source: Medscape Today Headlines [2014.07.18]
Inhaled corticosteroids may suppress growth in the first year of treatment in children with asthma, but lower doses may minimize the effects, according to 2 Cochrane reviews.
Medscape Medical News

Asthma medication linked to growth suppression in children
Source: Respiratory / Asthma News From Medical News Today [2014.07.17]
A review of past studies has found that inhaled corticosteroids used to treat asthma could result in restricting the growth of children who have the condition.

Progress in allergic asthma research after ingestion of fruits
Source: Allergy News From Medical News Today [2014.07.16]
Researchers at the UPM suggest that the interaction between two proteins can be the responsible for the allergic asthma episodes after eating an infected fruit.

Active genetic neighborhoods scoured for genes that can be targeted to treat asthmatic disease
Source: Respiratory / Asthma News From Medical News Today [2014.07.10]
In a study published in the scientific journal Nature Immunology, a group at the La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D.

Prediction Update: Asthma
Source: MedPage Today Allergy & Immunology [2014.07.10]
(MedPage Today) -- In January, we asked, "What will be the most important clinical development in asthma in 2014?" Now, at the half-year mark, we return to our experts to ask how their predictions are holding up.

more news >>

Published Studies Related to Quibron-T (Theophylline)

Beneficial effects of theophylline infusions in surgical patients with intra-abdominal hypertension. [2011.08]
BACKGROUND: Intra-abdominal hypertension (IAH) can cause high mortality. Recently, we found that IAH was associated with increased serum levels of adenosine and interleukin 10. Our present "hypothesis-generated study" was based on the above mentioned results... CONCLUSIONS: Adenosine receptor antagonism with T following IAH diagnosis resulted in markedly reduced mortality in patients with moderated IAH (<20 mmHg). Theophylline-associated mortality reduction may be related to improved renal perfusion and improved MAP, presumably caused by adenosine receptor blockade. Because this study was not a randomized controlled study, these compelling observations require further multicentric clinical confirmation.

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults. [2011.07]
OBJECTIVE: To investigate whether a pharmacokinetic drug-drug interaction exists between theophylline (THEO), a CYP1A2 substrate with a narrow therapeutic index, and the concomitant substrate roflumilast (ROF), a novel selective PDE4 inhibitor partially metabolized by CYP1A2... CONCLUSIONS: Neither ROF nor its main metabolite had any impact on the metabolism of the concomitant CYP1A2 substrate THEO in humans. Though co-administration of THEO resulted in a minor increase (28%) in total ROF exposure, no safety or tolerability concerns and no altered total PDE4 inhibition of both ROF and R-NO, were observed.

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.11]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. [2010.09.29]
Although the optimal strategy for preventing contrast-induced acute kidney injury (CI-AKI) has not yet been established, the current strategy focuses on adequate periprocedural hydration, the use of a low amount of low or iso-osmolar contrast medium, and the application of adjunctive therapies, including hemofiltration, hemodialysis and drugs...

Adenosine receptor inhibition with theophylline attenuates the skin blood flow response to local heating in humans. [2010.09]
Mechanisms underlying the robust cutaneous vasodilatation in response to local heating of human skin remain unresolved. Adenosine receptor activation has been shown to induce vasodilatation via nitric oxide, and a substantial portion of the plateau phase to local heating of human skin has been shown to be dependent on nitric oxide...

more studies >>

Clinical Trials Related to Quibron-T (Theophylline)

Rosiglitazone Versus Theophylline in Asthmatic Smokers [Completed]
Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence of smoking in asthmatics runs between 20-30%. Therefore, new, more efficacious treatments are required.

Recent work has demonstrated a mechanism which may explain steroid resistance. A commonly used drug called theophylline can reverse this steroid resistance in laboratory studies. Another commonly used drug, rosiglitazone can reverse smoking induced lung inflammation in laboratory studies.

The investigators aim to study the effects of these drugs on smoking asthmatics' lung function and other parameters including quality of life and asthma control.

All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab [Recruiting]
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.

Theophylline in Chronic Obstructive Pulmonary Disease [Recruiting]
This will be a prospective randomized double-blinded parallel group clinical trial evaluating the short-term effects of theophylline therapy on exercise duration and lung function in patients with chronic obstructive pulmonary disease already receiving both tiotropium and a long-acting beta-agonist (salmeterol or formoterol).

Theophylline in Treating Cancer Patients With Shortness of Breath [Active, not recruiting]
RATIONALE: Theophylline may help to relieve shortness of breath in patients who have cancer. It is not yet known whether theophylline is more effective than no further treatment for shortness of breath.

PURPOSE: Randomized phase III trial to determine the effectiveness of theophylline in treating shortness of breath in patients who have cancer.

Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia [Completed]
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of theophylline in treating patients who have in situ, stage I, or stage II chronic lymphocytic leukemia.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Quibron-T has an overall score of 5. The effectiveness score is 4 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Quibron-T review by 52 year old female patient

  Rating
Overall rating:  
Effectiveness:   Marginally Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   asthma
Dosage & duration:   300 mg 2x day taken daily for the period of about 10 years
Other conditions:   migraines, depression
Other drugs taken:   birth control, proventil inhaler
  
Reported Results
Benefits:   the medication kept my asthma under control or so i thought. as an aside, i still have a few left and every so often if i am out of my migraine medication, i will take a theodur and it seems to alleviate the headache. it was inexpensive.
Side effects:   while I was on it, i never really experienced any side effects. except one time when i accidently took too much and became dizzy and nauseaus. when i went off it i suffered two weeks of migraines due to withdrawal.
Comments:   i took 300 mg. twice a day and also used an inhaler regularly. i assumed it was as good as it gets. my new asthma specialist determined i had suffered some loss of lung function as the asthma had not been controlled as well as it could have been. i had to have regular blood work to determine the levels were right.

See all Quibron-T reviews / ratings >>

Page last updated: 2014-07-18

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014